Last reviewed · How we verify
Thalidomide, Melphalan, Prednisone
This combination uses thalidomide as an immunomodulatory agent, melphalan as an alkylating chemotherapy, and prednisone as a corticosteroid to treat multiple myeloma through multiple mechanisms including immune activation, DNA damage, and anti-inflammatory effects.
This combination uses thalidomide as an immunomodulatory agent, melphalan as an alkylating chemotherapy, and prednisone as a corticosteroid to treat multiple myeloma through multiple mechanisms including immune activation, DNA damage, and anti-inflammatory effects. Used for Multiple myeloma in patients ineligible for autologous stem cell transplantation.
At a glance
| Generic name | Thalidomide, Melphalan, Prednisone |
|---|---|
| Sponsor | Grupo de Estudos Multicentricos em Onco-Hematologia |
| Drug class | Combination chemotherapy with immunomodulatory agent |
| Target | Multiple targets: cereblon (thalidomide), DNA (melphalan), glucocorticoid receptor (prednisone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Thalidomide enhances T-cell proliferation and IL-2 production while inhibiting TNF-α, melphalan causes DNA crosslinking and cell death in rapidly dividing myeloma cells, and prednisone provides anti-inflammatory and immunosuppressive effects. This triple combination (MPT regimen) is designed to improve response rates and survival in multiple myeloma patients, particularly those ineligible for stem cell transplantation.
Approved indications
- Multiple myeloma in patients ineligible for autologous stem cell transplantation
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Peripheral neuropathy
- Infection
- Venous thromboembolism
- Hyperglycemia
Key clinical trials
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (PHASE3)
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma (PHASE1)
- Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients (PHASE3)
- Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone (NA)
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (PHASE3)
- Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients (PHASE3)
- S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma (PHASE2)
- Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: